ImmunoCellular Therapeutics, Ltd., which trades on the OTC Markets under the ticker IMUC, is a Los Angeles-based company developing immune-based therapies to treat cancer. As of July 9, 2020, ImmunoCellular Therapeutics, Ltd. was trading at $0.03 per share, according to Yahoo! Finance
ImmunoCellular Therapeutics
ImmunoCellular’s flagship research program is called Stem-to-T-Cell. What is the Stem-to-T-Cell research initiative? The initiative is dedicated to engineering hematopoietic stem cells to generate cytotoxic T cells. ImmunoCellullar is also “seeking partners” for clinical-stage programs. These programs include immunotherapies that are based on dendritic cells and are trying to target solid tumors. The specific immunotherapies are ICT-107, ICT-121, and ICT-140. Let’s look at these therapies in further detail. 
ICT-107 is an immunotherapy focusing on dendrites. It targets tumor-associated antigens on glioblastoma stem cells. While ImmunoCellular was engaged in a Phase 3 clinical trial in newly-diagnosed glioblastoma, that clinical trial has been suspended. 
ICT-121 is an immunotherapy targeting an antigen associated with cancer stem cells. There has been a Phase 1 clinical trial in patients with recurrent glioblastoma; that trial has been completed. 
ICT-140 is an immunotherapy that targets antigens associated with ovarian cancer. There are seven antigens, including those expressed by cancer stem cells. 
It is important to note that these therapies are still in the early stages of development; none have yet made it to market.  Investors should understand that biopharmaceutical companies are notoriously risky and volatile. In the era of COVID-19, as different companies scramble to develop therapies, investors should carefully evaluate the merits of a given company or offering before investing. 
If you invested in ImmunoCellular Therapeutics and have questions about your investment, don’t hesitate to contact the securities attorneys of Fitapelli Kurta. Call (877) 238-4175 or email for your free case consultation with a securities attorney.